<DOC>
	<DOC>NCT01631396</DOC>
	<brief_summary>The study is a prospective, single center, double arm study aiming at the comparison of 2 commercial neuromuscular block reversal drugs: Neostigmine (Cooper S.A.) and Sugammadex (MSD). A faster recovery from neuromuscular block is expected for patients receiving Sugammadex and this protocol is of high importance for anesthesia of morbid obese patients during bariatric surgery.</brief_summary>
	<brief_title>Comparison of Two Neuromuscular Anesthetics Reversal in Obese Patient Undergoing Bariatric Surgery</brief_title>
	<detailed_description />
	<mesh_term>Anesthetics</mesh_term>
	<mesh_term>Neostigmine</mesh_term>
	<mesh_term>Rocuronium</mesh_term>
	<criteria>1. Morbidly obese male or female patients in the age 2065 that are candidates for bariatric surgery. 2. Patients that can read and understand the fundamental nature of the clinical protocol. 3. Patients must sign the Informed Consent Form. 1. Patients treated with drugs that might interact with Rocuronium. 2. Patients with history of malignant hyperthermia. 3. Patients with significant renal disease. 4. Patients with a known allergy to one of the drugs used during anesthesia. 5. Patients with known muscular disease. 6. Patients with severe cardiovascular disease (NYHA&gt;2) 7. Breast feeding patients 8. Patients refusing to follow the clinical protocol. 9. Patients participating in a different clinical trial. 10. Patients refusing to sign the Informed Consent Form 11. Physician's objection.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Morbid obesity</keyword>
	<keyword>Bariatric Surgery</keyword>
	<keyword>Neuromuscular block reversal</keyword>
</DOC>